Clinical Trials on Chronic Eosinophilic Leukemia, Not Otherwise Specified in China

Total 60 results

National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Double-Expressor Lymphoma | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma, Not Otherwise... and other conditions

United States
Chongqing University Cancer Hospital

Recruiting

Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

China
CytoCares Inc

Recruiting

Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies

Chronic Lymphocytic Leukemia | Non-hodgkin Lymphoma | Acute Lymphoblastic Leukaemia

China
Wuhan Union Hospital, China
Beijing GoBroad Hospital Management Co.,Ltd; Shanghai YaKe Biotechnology Ltd.

Recruiting

Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies

T-Cell Lymphocytic Leukemia | T-Cell Chronic Lymphocytic Leukemia | T Cell Non-Hodgkin Lymphoma

China
Ou Bai, MD/PHD
Second Hospital of Jilin University; China-Japan Union Hospital, Jilin University

Recruiting

Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.

Angioimmunoblastic T-cell Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise Specified

China
Beijing Boren Hospital

Recruiting

Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Acute Lymphocytic Leukemia

China
Zhujiang Hospital
Guangdong Zhaotai Cell Bio-tech Co., LTD

Withdrawn

CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma (CAR19T2)

B-cell Acute Lymphoblastic Leukemia | B-Cell Lymphoma, Unspecified

China
Nanjing Sanhome Pharmaceutical, Co., Ltd.

Unknown

Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | B-Cell Non-Hodgkin Lymphomas(NHL)

China
Wuhan Union Hospital, China
Shanghai Simnova Biotechnology Co.,Ltd.

Recruiting

Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies

Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Non Hodgkin's Lymphoma

China
The First Affiliated Hospital with Nanjing Medical...
Guangzhou Lupeng Pharmaceutical Company LTD.; Newave Pharmaceutical Inc

Recruiting

A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma

Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma

China
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Active, not recruiting

A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

China
Institute of Hematology & Blood Diseases Hospital
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Beijing...

Unknown

γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkin's Lymphoma | Peripheral T Cell Lymphoma | Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma | Chronic Lymphoblastic Leukemia

China
Shandong Provincial Hospital

Recruiting

Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Non Hodgkin Lymphoma | High Grade B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

China
Beijing Sport University

Completed

Effects of Online Exercise Intervention on Physical and Mental Conditions in Young Adults With Chronic Neck Pain

Chronic Non-specific Neck Pain

China
Zhejiang DTRM Biopharma

Completed

Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas

Chronic Lymphocytic Leukemia | B-cell Lymphomas

China
Shanghai YingLi Pharmaceutical Co. Ltd.

Unknown

A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies

B-cell Chronic Lymphocytic Leukemia | B-cell Lymphoma Recurrent

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Lymphoma, B-Cell | Leukemia, B-cell

China
Hoffmann-La Roche

Completed

A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease

Lymphocytic Leukemia, Chronic, Diffuse Large B-cell Lymphoma, Follicular Lymphoma

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital; The First People's Hospital of Hefei; Hefei Binhu...

Unknown

CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | B-cell Prolymphocytic Leukemia

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First People's Hospital of Hefei; Hefei Binhu Hospital

Unknown

PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | B-cell Prolymphocytic Leukemia

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Unknown

Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | B-cell Prolymphocytic Leukemia

China
Chongqing Precision Biotech Co., Ltd

Recruiting

CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Lymphoma, B-Cell | Leukemia, B-cell

China
First Affiliated Hospital Xi'an Jiaotong University
Eureka Therapeutics Inc.

Unknown

ET190L1-ARTEMIS™ T Cells in Relapsed, Refractory B Cell Leukemia and Lymphoma

CD19+ Lymphoma, B-Cell | CD19+ Leukemia, B-Cell

China
Chongqing Precision Biotech Co., Ltd

Recruiting

CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Leukemia | Leukemia, Lymphocytic, Chronic, B-Cell | Leukemia, B-cell

China
GOG Foundation
National Cancer Institute (NCI)

Active, not recruiting

Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery

Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Stage IIA Cervical Cancer AJCC v7 | Stage IB Cervical Cancer AJCC v6 and v7 | Stage I Cervical Cancer AJCC v6 and v7 | Stage IA Cervical Cancer AJCC v6 and v7

United States, Korea, Republic of, Japan
Shenzhen Second People's Hospital

Unknown

CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT

Lymphoma, B-Cell | Leukemia, Lymphocytic, Chronic, B-Cell | Leukemia, Lymphocytic, Acute, B-Cell

China
Southwest Hospital, China

Unknown

a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies

Lymphoma, Large B-Cell, Diffuse | Leukemia, Lymphocytic, Chronic, B-Cell | Lymphoma，Malignant

China
Shandong Provincial Hospital

Recruiting

Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

Mantle Cell Lymphoma | Diffuse Large B-cell Lymphoma | High Grade B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | B-cell NonHodgkin Lymphoma

China
Peking University Third Hospital

Recruiting

Research on Influencing Factors of Compliance of Spinal Exercise Therapy

Non-specific Chronic Low Back Pain

China
Chinese PLA General Hospital

Completed

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19 (CART19)

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | Prolymphocytic Leukemia and other conditions

China
Chinese PLA General Hospital

Unknown

Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
MingSight Pharmaceuticals, Inc
Shenzhen MingSight Relin Pharmaceutical Co., Ltd

Recruiting

A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Relapsed or Refractory B-cell Lymphoma | Marginal Zone Lymphoma (MZL)

China
The University of Hong Kong
The Queen Elizabeth Hospital

Completed

Clinical Electrophysiology Assessment for Low Back Pain (LBP)

Non Specific Chronic Low Back Pain

China
Gustave Roussy, Cancer Campus, Grand Paris
Children's Oncology Group

Unknown

Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients

B-cell Non Hodgkin Lymphoma | Mature B-cell Leukemia Burkitt-type

Belgium, France, United Kingdom, Netherlands, Canada, Hungary, Italy, Poland, Spain, China
GOG Foundation
National Cancer Institute (NCI)

Completed

Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer

Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Stage IIA Cervical Cancer AJCC v7 | Stage IIB Cervical Cancer AJCC v6 and v7 | Stage IIIB Cervical Cancer AJCC v6 and v7 | Stage IVA Cervical Cancer AJCC v6 and v7 | Stage IB Cervical...

United States, Canada, Saudi Arabia, China, Singapore
Centaurus Biopharma Co., Ltd.

Unknown

Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Chronic Lymphocytic Leukemia | Waldenstrom's Macroglobulinemia | Diffuse Large B Cell Lymphoma | Relapsed or Refractory B Cell Non-Hodgkin Lymphoma | Mantle Zone Lymphoma Refractory/Recurrent | Follicle Centre Lymphoma Diffuse

China
Nanfang Hospital of Southern Medical University

Recruiting

Induced-T Cell Like NK Cells for B Cell Malignancies

B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia | B Cell Leukemia | B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent

China
BeiGene

Recruiting

A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

Refractory Chronic Lymphocytic Leukemia | Refractory Non-Hodgkin Lymphoma | Relapsed Follicular Lymphoma | Refractory Small Lymphocytic Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Refractory Diffuse Large B-cell Lymphoma | Transformed Non-Hodgkin Lymphoma | Relapsed... and other conditions

China, Australia
The Second Affiliated Hospital of Henan University...
Xuzhou Medical University; Xinqiao Hospital of Chongqing

Unknown

Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma (MatchCART)

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
AstraZeneca

Active, not recruiting

Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies

Phase I: Relapsed or Refractory B-cell Malignancies | Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma | Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia

China
Wuhan Union Hospital, China
Wuhan Si'an Medical Technology Co., Ltd

Recruiting

Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma

Follicular Lymphoma | Burkitt Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma

China
Ruijin Hospital

Unknown

CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma

ALK-negative Anaplastic Large Cell Lymphoma | Peripherial T Cell Lymphoma,Not Otherwise Specified | Angioimmunoblastic T Cell Lymphoma | Enteropathy Associated T Cell Lymphoma | Hepatosplenic T Cell Lymphoma | Subcutaneous Panniculitis Like T Cell Lymphoma

China
Merck Sharp & Dohme LLC

Recruiting

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Non-Hodgkins Lymphoma | Hematologic Malignancies | Chronic Lymphocytic Leukaemia | Waldenstroms Macroglobulinaemia

Poland, United States, Argentina, Australia, Brazil, Canada, France, Israel, Italy, Spain, Switzerland, Turkey, United Kingdom, Korea, Republic of, Germany, Denmark, China, Romania, Czechia, Hungary, Ireland, Ukraine
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Lymphoma, Non-Hodgkin | Leukemia, Lymphocytic, Chronic, B-Cell

United States, China, France, Denmark, Israel, Poland, Australia
Celgene Corporation

Terminated

Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Multiple Myeloma | Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Non-Hodgkin Lymphoma

Japan
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Lymphoma, Non-Hodgkin | Leukemia, Lymphocytic, Chronic, B-Cell

United States, Korea, Republic of, Israel, Japan, Germany, Spain, Australia, China, France, United Kingdom, Greece, Italy
BeiGene

Recruiting

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Follicular Lymphoma | Waldenström Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | B-cell Malignancy | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Richter's Transformation | DLBCL Unclassifiable

China
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)

Recruiting

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | MALT Lymphoma | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Indolent Lymphoma | Refractory B-Cell Lymphoma

United States, Australia, China

Clinical Trials on Chronic Eosinophilic Leukemia, Not Otherwise Specified in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations